Header image

Transforming global genetic data into medical decisions

Our goal is the rapid medical diagnosis of inherited diseases, provided at the earliest possible moment as we turn analytical information into actionable results for physicians, patients and pharmaceutical partners.

Our commitment to the global medical community is an early and precise diagnosis for continuous improvement of therapeutic options for each individual patient.

Latest Scientific News

Confirmation of ACER3-related recessive neurodegeneration

Learn more about our recent findings in confirmation of ACER3-related recessive…

Association of hydrocephalus and renal dysplasia

Read more about our recent findings in association of hydrocephalus and renal dysplasia…

Novel clinical and genetic insights into dysfunction of the ASC-1 complex

The transcriptional coactivator ASC-1 complex is composed of four subunits ASC-1 (TRIP4),…

HTRA2 Defect: a recognizable inborn error of metabolism

Neonatal-onset movement disorders, especially in combination with seizures, are rare and…

Customer Feedback

Give feedback

Newsletter subscription

NORTHFIELD, IL. — The College of American Pathologists (CAP), a Center for Medicare and Medicaid Services (CMS)-approved accreditation authority, has awarded...

Read more

Provides physicians with virtual encyclopedia of genetic information at their fingertips for improved and efficient diagnosis of rare diseases

Read more

CENTOGENE and Denali Therapeutics (NASDAQ: DNLI) today announced a strategic collaboration for the global identification and recruitment of LRRK2 mutation...

Read more

Joint drug discovery projects combine CENTOGENE’s patient access and biomarker expertise with Evotec's leading IPSC platform

Read more

We are proud to have been honored with the award from the Federal State Government of Mecklenburg-Vorpommern in the category ‘Company Development’. We are...

Read more

CENTOGENE announced today a partnering with the Medical Faculties of the Universities of Greifswald and Rostock for the research project, “Development of...

Read more

CENTOGENE announced today the opening of its first U.S. based rare disease laboratory in Cambridge, Massachusetts.  The new facility, opening on August 1, 2018,...

Read more

CENTOGENE, driving the diagnostic workflows and individualized therapeutic decisions not only in rare diseases but also in oncological setups is proud to host...

Read more

CENTOGENE, the worldwide leader in using genetic and proteomic knowledge to enable patients, clinicians and pharmaceutical partners to identify and accelerate...

Read more